Biopreservation Market by Product Type (Consumables, Equipment), Technology (Cryopreservation, Hypothermic Storage, Lyophilization), Sample Type, Application, End User - Global Forecast 2025-2032
Description
The Biopreservation Market was valued at USD 3.64 billion in 2024 and is projected to grow to USD 4.57 billion in 2025, with a CAGR of 27.92%, reaching USD 26.11 billion by 2032.
An authoritative orientation to why resilient, standardized preservation practices are now central to clinical, research, and commercial bioproduct workflows
The preservation of biological materials underpins contemporary advances across healthcare, research, and industrial biotechnology. As biobanks, cell therapy developers, and transplant programs scale, the need for robust preservation infrastructure and consumables has moved from a niche operational concern to a strategic element of product pipelines and clinical workflows. This transition is driven by the convergence of increasingly complex cell- and tissue-based therapeutics, higher regulatory scrutiny for long-term sample integrity, and operational demands for reproducible storage and transport conditions.
In practice, organizations face a growing set of technical and logistical challenges that require integrated solutions. Innovations in cryopreservation protocols, hypothermic transport systems, and vitrification techniques are reshaping both laboratory practice and commercial manufacturing. At the same time, supply chain resilience and regulatory harmonization are becoming critical enablers of scalability. Taken together, these forces are prompting stakeholders to rethink procurement strategies, validation plans, and long-term partnerships with suppliers to ensure biological materials remain viable from discovery through to clinical application.
How technological maturation, regulatory focus, and supply chain integration are collectively redefining standards and buyer expectations across preservation ecosystems
The biopreservation landscape is undergoing a set of transformative shifts that are altering technology adoption patterns, stakeholder expectations, and the configuration of value chains. Emerging cell and gene therapies require more reliable cryostorage and transport capabilities, which has elevated investments in both hardware, such as ultra-low temperature freezers and advanced monitoring solutions, and in consumables including cryoprotectants and single-use storage vessels. Parallel advances in technologies such as vitrification and lyophilization are opening new possibilities for long-term stability of complex biologics, which in turn is reshaping how developers design clinical supply chains and stability programs.
Concurrently, regulatory authorities are increasing attention to the cold chain and sample traceability, driving demand for integrated monitoring systems and standardized validation frameworks. Market participants are responding with strategic partnerships that link equipment makers, consumable suppliers, and contract service providers. Finally, maturity in automation and digitalization is enabling real-time condition monitoring, predictive maintenance, and data-driven quality assurance, all of which contribute to more resilient and efficient preservation ecosystems. These shifts collectively raise the bar for operational excellence and create opportunities for suppliers that can demonstrate validated performance, regulatory alignment, and scalability.
Assessment of how tariffs are prompting supply chain restructuring, procurement shifts, and resilience-driven investment across preservation infrastructure
The imposition and persistence of tariffs have introduced a layer of commercial complexity that affects multiple elements of the biopreservation supply chain. Increased duties on imported equipment and materials can raise landed costs for cryogenic freezers, monitoring electronics, and specialized consumables. As a result, procurement teams face compressed margins and may re-evaluate capital investment timelines, service contracts, and vendor sourcing strategies to preserve budget flexibility and operational readiness.
Beyond direct cost implications, tariffs can amplify lead-time risks by incentivizing sourcing shifts and stockpiling behaviors. Manufacturers that previously relied on cross-border component sourcing may pursue alternative supplier relationships, nearshoring, or redesign of product bills of materials to mitigate tariff exposure. This reconfiguration of supply networks can create transitional capacity constraints and uneven regional availability of critical items such as DMSO, glycerol, certified vials, and precision monitoring systems. In turn, downstream stakeholders including research institutes, fertility centers, blood banks, and clinical manufacturers may face increased procurement complexity and a need to validate new suppliers and components, which can extend qualification timelines and require additional compliance documentation.
Operationally, tariff-driven cost pressures can accelerate consolidation among suppliers and encourage vertical integration as firms seek to internalize more of the value chain to protect margins. At the same time, buyers and service providers are more actively engaging in scenario planning and stress-testing their cold chains to ensure continuity. Strategic responses frequently emphasize diversification, long-term supplier agreements, and investment in modular or scalable equipment that can be upgraded locally to reduce cross-border exposure. While tariffs introduce short- to medium-term disruption, they also catalyze a broader reassessment of resilience and total cost of ownership across preservation operations.
Integrated segmentation insights revealing how product classes, preservation technologies, sample categories, applications, and end users together shape procurement priorities and innovation pathways
A nuanced segmentation framework is essential for understanding demand drivers and technology-fit across diverse end uses and product classes. When considering product type distinctions, it is useful to view the universe as consumables versus equipment; consumables encompass cryoprotectants, media, and vials and tubes, with cryoprotectants further differentiated by DMSO and glycerol, while equipment covers cryogenic freezers, monitoring systems, and storage systems. This product-level lens clarifies where recurring spend concentrates and where capital expenditure requirements are most pronounced, informing procurement cycles and validation activities.
Technology-based segmentation highlights distinct preservation approaches-cryopreservation, hypothermic storage, lyophilization, and vitrification-each with unique process controls, regulatory considerations, and suitability for different biological constructs. Sample type segmentation differentiates demand stemming from biological fluids, blood components, cells, organs, and tissues, which influences required storage temperatures, shipping modalities, and quality controls. Application-focused segmentation connects technologies to clinical and research use cases such as assisted reproductive technology, blood preservation, cell therapy, organ preservation, and tissue engineering, elucidating where specialized solutions and validation protocols are most needed. Finally, end-user segmentation across blood banks, fertility clinics, hospitals and clinics, pharmaceutical and biotech companies, and research institutes reveals divergent buying behavior, budget cycles, and risk tolerance, which together shape supplier engagement strategies and service models.
By integrating these segmentation dimensions, executives can better prioritize product development, align manufacturing capacity to specific clinical workflows, and design commercial strategies that reflect distinct pricing dynamics, regulatory paths, and end-user validation requirements.
Regional dynamics and policy influences that determine adoption pacing, distribution strategies, and operational investments across the Americas, EMEA, and Asia-Pacific
Regional dynamics exert a strong influence on regulatory approaches, supply chain resilience, and customer adoption patterns. In the Americas, institutional infrastructure and established clinical trial networks support early adoption of advanced preservation technologies and the integration of digital monitoring across biobanks and cell therapy manufacturing. This environment incentivizes investments in large-scale storage systems and validated consumables that meet stringent chain-of-custody requirements.
Across Europe, Middle East & Africa, policy harmonization efforts and a diverse regulatory landscape influence how suppliers position their compliance dossiers and distribution networks. Variability in reimbursement frameworks and public health priorities shapes demand for blood preservation solutions and organ transport innovations, while cross-border logistics and customs practices impact procurement lead times and inventory strategies. In the Asia-Pacific region, rapid capacity expansion in pharmaceutical production, contract development and manufacturing organizations, and fertility services is accelerating demand for both capital equipment and consumables. Local manufacturing capabilities, government investment in biotechnology infrastructure, and regional trade policies all contribute to differentiated adoption rates and partnership models. Understanding these regional distinctions is essential for designing market entry strategies, prioritizing distribution investments, and tailoring training and validation support to local regulatory and operational contexts.
Competitive behaviors and supplier strategies that prioritize validated system packages, interoperable monitoring, and service-led differentiation in preservation provision
Competitive dynamics in the preservation space are characterized by a mix of specialized manufacturers, diversified life science suppliers, and service-oriented providers that offer integrated cold-chain solutions. Key commercial behaviors include differentiated product portfolios that combine validated consumables with matched equipment, strategic alliances that link instrumentation providers with contract service organizations, and targeted investments in automation and remote monitoring capabilities. These approaches help suppliers reduce friction for buyers and shorten qualification periods by delivering end-to-end validated systems.
Market leaders increasingly pursue modular offerings that allow clients to scale storage capacity and monitoring sophistication in line with evolving clinical or research needs. At the same time, smaller niche players focus on high-performance consumables or specialized cryoprotectant formulations that address particular biological substrates. Service models are also evolving: providers offer not only hardware and materials, but also installation qualification, preventive maintenance, and data integration services to support regulatory compliance and continuous quality assurance. For purchasers, the ability of a supplier to demonstrate interoperable systems, robust validation packages, and responsive technical support is becoming a primary selection criterion, and strategic partnerships between manufacturers and service providers are becoming more common as firms seek to offer turnkey solutions.
Actionable priorities for executives to strengthen supply resilience, accelerate validation, and differentiate through modular systems and service excellence
Industry leaders should prioritize resilience, regulatory alignment, and customer-centric service design to capture the strategic opportunities emerging in preservation. First, procurement and sourcing strategies must incorporate supplier diversification, long-term agreements for critical consumables, and contingency planning for equipment lead times; such measures reduce operational vulnerability and provide predictable supply continuity. Second, investments in interoperable monitoring systems and validated process documentation should be elevated to core capabilities, as these elements materially reduce qualification timelines and increase buyer confidence across clinical and research settings.
In parallel, suppliers should design modular product architectures that enable incremental capacity expansion and minimize the need for full-system replacement. Collaboration with contract development and manufacturing partners, clinical networks, and accreditation bodies will streamline validation pathways and promote broader adoption. Finally, executives should develop clear migration plans that align legacy systems with next-generation preservation technologies, including training programs and support contracts that lower the barrier to change and protect long-term customer relationships. Taking these actions will position organizations to sustain operations through external shocks while enabling growth in emerging therapeutic and clinical applications.
Transparent research approach combining primary stakeholder interviews, technical specification review, and rigorous triangulation to ensure robust analytical conclusions
A transparent and reproducible research methodology underpins credible analysis of preservation markets and technology adoption. Primary data collection combines structured interviews with procurement leads, technical operations managers, and clinical end users, supplemented by comparative analysis of supplier technical specifications, regulatory filings, and publicly available clinical study protocols. Secondary research sources include peer-reviewed literature, standards guidance from accreditation bodies, and industry white papers that document best practices in cold-chain management and sample integrity.
Quantitative and qualitative inputs are triangulated to ensure internal consistency, with case studies used to illustrate typical qualification processes, common failure modes, and successful mitigation strategies. Validation of findings includes cross-verification with independent technical experts and review of actual equipment performance metrics where available. The methodology emphasizes transparency in data provenance, clear documentation of assumptions, and sensitivity checks for scenarios related to supply disruptions and regulatory shifts. This approach ensures that conclusions are grounded in observable behavior and technical constraints rather than conjecture alone.
Summary conclusions on the strategic importance of validated preservation systems, resilient sourcing, and integrated service models to enable clinical and research advancement
Sustained advances in preservation technologies and an increased focus on supply chain resilience are reshaping how biological materials are stored, transported, and validated. Stakeholders from clinical practitioners to contract manufacturers are adapting procurement models, investing in monitoring and validation capabilities, and seeking partnerships that reduce operational friction and support regulatory compliance. As a result, the ecosystem is moving toward more integrated solutions that bundle hardware, consumables, and services with the data capabilities required for traceability and quality assurance.
Looking ahead, resilience and interoperability will remain central to competitive differentiation. Organizations that align product development with stringent validation protocols, invest in modular and upgradeable systems, and cultivate diversified sourcing will be best positioned to support expanding clinical and research use cases. By emphasizing validated performance, responsive technical support, and strategic partnerships, stakeholders can reduce risk, improve reproducibility, and unlock the full potential of cell, tissue, and organ-based innovations.
Please Note: PDF & Excel + Online Access - 1 Year
An authoritative orientation to why resilient, standardized preservation practices are now central to clinical, research, and commercial bioproduct workflows
The preservation of biological materials underpins contemporary advances across healthcare, research, and industrial biotechnology. As biobanks, cell therapy developers, and transplant programs scale, the need for robust preservation infrastructure and consumables has moved from a niche operational concern to a strategic element of product pipelines and clinical workflows. This transition is driven by the convergence of increasingly complex cell- and tissue-based therapeutics, higher regulatory scrutiny for long-term sample integrity, and operational demands for reproducible storage and transport conditions.
In practice, organizations face a growing set of technical and logistical challenges that require integrated solutions. Innovations in cryopreservation protocols, hypothermic transport systems, and vitrification techniques are reshaping both laboratory practice and commercial manufacturing. At the same time, supply chain resilience and regulatory harmonization are becoming critical enablers of scalability. Taken together, these forces are prompting stakeholders to rethink procurement strategies, validation plans, and long-term partnerships with suppliers to ensure biological materials remain viable from discovery through to clinical application.
How technological maturation, regulatory focus, and supply chain integration are collectively redefining standards and buyer expectations across preservation ecosystems
The biopreservation landscape is undergoing a set of transformative shifts that are altering technology adoption patterns, stakeholder expectations, and the configuration of value chains. Emerging cell and gene therapies require more reliable cryostorage and transport capabilities, which has elevated investments in both hardware, such as ultra-low temperature freezers and advanced monitoring solutions, and in consumables including cryoprotectants and single-use storage vessels. Parallel advances in technologies such as vitrification and lyophilization are opening new possibilities for long-term stability of complex biologics, which in turn is reshaping how developers design clinical supply chains and stability programs.
Concurrently, regulatory authorities are increasing attention to the cold chain and sample traceability, driving demand for integrated monitoring systems and standardized validation frameworks. Market participants are responding with strategic partnerships that link equipment makers, consumable suppliers, and contract service providers. Finally, maturity in automation and digitalization is enabling real-time condition monitoring, predictive maintenance, and data-driven quality assurance, all of which contribute to more resilient and efficient preservation ecosystems. These shifts collectively raise the bar for operational excellence and create opportunities for suppliers that can demonstrate validated performance, regulatory alignment, and scalability.
Assessment of how tariffs are prompting supply chain restructuring, procurement shifts, and resilience-driven investment across preservation infrastructure
The imposition and persistence of tariffs have introduced a layer of commercial complexity that affects multiple elements of the biopreservation supply chain. Increased duties on imported equipment and materials can raise landed costs for cryogenic freezers, monitoring electronics, and specialized consumables. As a result, procurement teams face compressed margins and may re-evaluate capital investment timelines, service contracts, and vendor sourcing strategies to preserve budget flexibility and operational readiness.
Beyond direct cost implications, tariffs can amplify lead-time risks by incentivizing sourcing shifts and stockpiling behaviors. Manufacturers that previously relied on cross-border component sourcing may pursue alternative supplier relationships, nearshoring, or redesign of product bills of materials to mitigate tariff exposure. This reconfiguration of supply networks can create transitional capacity constraints and uneven regional availability of critical items such as DMSO, glycerol, certified vials, and precision monitoring systems. In turn, downstream stakeholders including research institutes, fertility centers, blood banks, and clinical manufacturers may face increased procurement complexity and a need to validate new suppliers and components, which can extend qualification timelines and require additional compliance documentation.
Operationally, tariff-driven cost pressures can accelerate consolidation among suppliers and encourage vertical integration as firms seek to internalize more of the value chain to protect margins. At the same time, buyers and service providers are more actively engaging in scenario planning and stress-testing their cold chains to ensure continuity. Strategic responses frequently emphasize diversification, long-term supplier agreements, and investment in modular or scalable equipment that can be upgraded locally to reduce cross-border exposure. While tariffs introduce short- to medium-term disruption, they also catalyze a broader reassessment of resilience and total cost of ownership across preservation operations.
Integrated segmentation insights revealing how product classes, preservation technologies, sample categories, applications, and end users together shape procurement priorities and innovation pathways
A nuanced segmentation framework is essential for understanding demand drivers and technology-fit across diverse end uses and product classes. When considering product type distinctions, it is useful to view the universe as consumables versus equipment; consumables encompass cryoprotectants, media, and vials and tubes, with cryoprotectants further differentiated by DMSO and glycerol, while equipment covers cryogenic freezers, monitoring systems, and storage systems. This product-level lens clarifies where recurring spend concentrates and where capital expenditure requirements are most pronounced, informing procurement cycles and validation activities.
Technology-based segmentation highlights distinct preservation approaches-cryopreservation, hypothermic storage, lyophilization, and vitrification-each with unique process controls, regulatory considerations, and suitability for different biological constructs. Sample type segmentation differentiates demand stemming from biological fluids, blood components, cells, organs, and tissues, which influences required storage temperatures, shipping modalities, and quality controls. Application-focused segmentation connects technologies to clinical and research use cases such as assisted reproductive technology, blood preservation, cell therapy, organ preservation, and tissue engineering, elucidating where specialized solutions and validation protocols are most needed. Finally, end-user segmentation across blood banks, fertility clinics, hospitals and clinics, pharmaceutical and biotech companies, and research institutes reveals divergent buying behavior, budget cycles, and risk tolerance, which together shape supplier engagement strategies and service models.
By integrating these segmentation dimensions, executives can better prioritize product development, align manufacturing capacity to specific clinical workflows, and design commercial strategies that reflect distinct pricing dynamics, regulatory paths, and end-user validation requirements.
Regional dynamics and policy influences that determine adoption pacing, distribution strategies, and operational investments across the Americas, EMEA, and Asia-Pacific
Regional dynamics exert a strong influence on regulatory approaches, supply chain resilience, and customer adoption patterns. In the Americas, institutional infrastructure and established clinical trial networks support early adoption of advanced preservation technologies and the integration of digital monitoring across biobanks and cell therapy manufacturing. This environment incentivizes investments in large-scale storage systems and validated consumables that meet stringent chain-of-custody requirements.
Across Europe, Middle East & Africa, policy harmonization efforts and a diverse regulatory landscape influence how suppliers position their compliance dossiers and distribution networks. Variability in reimbursement frameworks and public health priorities shapes demand for blood preservation solutions and organ transport innovations, while cross-border logistics and customs practices impact procurement lead times and inventory strategies. In the Asia-Pacific region, rapid capacity expansion in pharmaceutical production, contract development and manufacturing organizations, and fertility services is accelerating demand for both capital equipment and consumables. Local manufacturing capabilities, government investment in biotechnology infrastructure, and regional trade policies all contribute to differentiated adoption rates and partnership models. Understanding these regional distinctions is essential for designing market entry strategies, prioritizing distribution investments, and tailoring training and validation support to local regulatory and operational contexts.
Competitive behaviors and supplier strategies that prioritize validated system packages, interoperable monitoring, and service-led differentiation in preservation provision
Competitive dynamics in the preservation space are characterized by a mix of specialized manufacturers, diversified life science suppliers, and service-oriented providers that offer integrated cold-chain solutions. Key commercial behaviors include differentiated product portfolios that combine validated consumables with matched equipment, strategic alliances that link instrumentation providers with contract service organizations, and targeted investments in automation and remote monitoring capabilities. These approaches help suppliers reduce friction for buyers and shorten qualification periods by delivering end-to-end validated systems.
Market leaders increasingly pursue modular offerings that allow clients to scale storage capacity and monitoring sophistication in line with evolving clinical or research needs. At the same time, smaller niche players focus on high-performance consumables or specialized cryoprotectant formulations that address particular biological substrates. Service models are also evolving: providers offer not only hardware and materials, but also installation qualification, preventive maintenance, and data integration services to support regulatory compliance and continuous quality assurance. For purchasers, the ability of a supplier to demonstrate interoperable systems, robust validation packages, and responsive technical support is becoming a primary selection criterion, and strategic partnerships between manufacturers and service providers are becoming more common as firms seek to offer turnkey solutions.
Actionable priorities for executives to strengthen supply resilience, accelerate validation, and differentiate through modular systems and service excellence
Industry leaders should prioritize resilience, regulatory alignment, and customer-centric service design to capture the strategic opportunities emerging in preservation. First, procurement and sourcing strategies must incorporate supplier diversification, long-term agreements for critical consumables, and contingency planning for equipment lead times; such measures reduce operational vulnerability and provide predictable supply continuity. Second, investments in interoperable monitoring systems and validated process documentation should be elevated to core capabilities, as these elements materially reduce qualification timelines and increase buyer confidence across clinical and research settings.
In parallel, suppliers should design modular product architectures that enable incremental capacity expansion and minimize the need for full-system replacement. Collaboration with contract development and manufacturing partners, clinical networks, and accreditation bodies will streamline validation pathways and promote broader adoption. Finally, executives should develop clear migration plans that align legacy systems with next-generation preservation technologies, including training programs and support contracts that lower the barrier to change and protect long-term customer relationships. Taking these actions will position organizations to sustain operations through external shocks while enabling growth in emerging therapeutic and clinical applications.
Transparent research approach combining primary stakeholder interviews, technical specification review, and rigorous triangulation to ensure robust analytical conclusions
A transparent and reproducible research methodology underpins credible analysis of preservation markets and technology adoption. Primary data collection combines structured interviews with procurement leads, technical operations managers, and clinical end users, supplemented by comparative analysis of supplier technical specifications, regulatory filings, and publicly available clinical study protocols. Secondary research sources include peer-reviewed literature, standards guidance from accreditation bodies, and industry white papers that document best practices in cold-chain management and sample integrity.
Quantitative and qualitative inputs are triangulated to ensure internal consistency, with case studies used to illustrate typical qualification processes, common failure modes, and successful mitigation strategies. Validation of findings includes cross-verification with independent technical experts and review of actual equipment performance metrics where available. The methodology emphasizes transparency in data provenance, clear documentation of assumptions, and sensitivity checks for scenarios related to supply disruptions and regulatory shifts. This approach ensures that conclusions are grounded in observable behavior and technical constraints rather than conjecture alone.
Summary conclusions on the strategic importance of validated preservation systems, resilient sourcing, and integrated service models to enable clinical and research advancement
Sustained advances in preservation technologies and an increased focus on supply chain resilience are reshaping how biological materials are stored, transported, and validated. Stakeholders from clinical practitioners to contract manufacturers are adapting procurement models, investing in monitoring and validation capabilities, and seeking partnerships that reduce operational friction and support regulatory compliance. As a result, the ecosystem is moving toward more integrated solutions that bundle hardware, consumables, and services with the data capabilities required for traceability and quality assurance.
Looking ahead, resilience and interoperability will remain central to competitive differentiation. Organizations that align product development with stringent validation protocols, invest in modular and upgradeable systems, and cultivate diversified sourcing will be best positioned to support expanding clinical and research use cases. By emphasizing validated performance, responsive technical support, and strategic partnerships, stakeholders can reduce risk, improve reproducibility, and unlock the full potential of cell, tissue, and organ-based innovations.
Please Note: PDF & Excel + Online Access - 1 Year
Table of Contents
186 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Implementation of automated cryopreservation systems to improve reproducibility and throughput in cell therapy manufacturing
- 5.2. Development of novel ice recrystallization inhibitors for enhanced viability of preserved biologics during long-term storage
- 5.3. Adoption of vitrification protocols in assisted reproductive technology to boost embryo and oocyte survival rates
- 5.4. Integration of sustainable cryogen-free preservation technologies to reduce costs and environmental impact in biobanking
- 5.5. Advances in lyophilization techniques for temperature-sensitive vaccines to extend shelf life without cold chain dependency
- 5.6. Regulatory harmonization efforts to standardize quality control criteria for global biopreservation workflows and materials
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Biopreservation Market, by Product Type
- 8.1. Consumables
- 8.1.1. Cryoprotectants
- 8.1.1.1. DMSO
- 8.1.1.2. Glycerol
- 8.1.2. Media
- 8.1.3. Vials & Tubes
- 8.2. Equipment
- 8.2.1. Cryogenic Freezers
- 8.2.2. Monitoring Systems
- 8.2.3. Storage Systems
- 9. Biopreservation Market, by Technology
- 9.1. Cryopreservation
- 9.2. Hypothermic Storage
- 9.3. Lyophilization
- 9.4. Vitrification
- 10. Biopreservation Market, by Sample Type
- 10.1. Biological Fluids
- 10.2. Blood Components
- 10.3. Cells
- 10.4. Organs
- 10.5. Tissues
- 11. Biopreservation Market, by Application
- 11.1. Assisted Reproductive Technology
- 11.2. Blood Preservation
- 11.3. Cell Therapy
- 11.4. Organ Preservation
- 11.5. Tissue Engineering
- 12. Biopreservation Market, by End User
- 12.1. Blood Banks
- 12.2. Fertility Clinics
- 12.3. Hospitals & Clinics
- 12.4. Pharmaceutical & Biotech Companies
- 12.5. Research Institutes
- 13. Biopreservation Market, by Region
- 13.1. Americas
- 13.1.1. North America
- 13.1.2. Latin America
- 13.2. Europe, Middle East & Africa
- 13.2.1. Europe
- 13.2.2. Middle East
- 13.2.3. Africa
- 13.3. Asia-Pacific
- 14. Biopreservation Market, by Group
- 14.1. ASEAN
- 14.2. GCC
- 14.3. European Union
- 14.4. BRICS
- 14.5. G7
- 14.6. NATO
- 15. Biopreservation Market, by Country
- 15.1. United States
- 15.2. Canada
- 15.3. Mexico
- 15.4. Brazil
- 15.5. United Kingdom
- 15.6. Germany
- 15.7. France
- 15.8. Russia
- 15.9. Italy
- 15.10. Spain
- 15.11. China
- 15.12. India
- 15.13. Japan
- 15.14. Australia
- 15.15. South Korea
- 16. Competitive Landscape
- 16.1. Market Share Analysis, 2024
- 16.2. FPNV Positioning Matrix, 2024
- 16.3. Competitive Analysis
- 16.3.1. Avantor, Inc.
- 16.3.2. Azenta, Inc.
- 16.3.3. Bio-Techne Corporation
- 16.3.4. BioCision LLC
- 16.3.5. BioLife Solutions, Inc.
- 16.3.6. Biomatrica, Inc.
- 16.3.7. Cryoport, Inc.
- 16.3.8. LabVantage Solutions, Inc.
- 16.3.9. Merck KGaA
- 16.3.10. MVE Biological Solutions
- 16.3.11. Panasonic Corporation
- 16.3.12. PHC Holdings Corporation
- 16.3.13. PrincetonCryo
- 16.3.14. Sartorius AG
- 16.3.15. Stirling Ultracold
- 16.3.16. Taylor-Wharton
- 16.3.17. Thermo Fisher Scientific Inc.
- 16.3.18. ThermoGenesis Holdings, Inc.
- 16.3.19. VWR International, LLC
- 16.3.20. X-Therma, Inc.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
